Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with >30,000 person-years of exposure. RESULTS. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. CONCLUSIONS. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide.

[1]  B. Clotet,et al.  Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). , 2010, Antiviral research.

[2]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[3]  P. Reiss,et al.  Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[4]  J. Lundgren Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients , 2008, AIDS.

[5]  C. Sabin,et al.  Abacavir and increased risk of myocardial infarction – Authors' reply , 2008, The Lancet.

[6]  Changyu Shen,et al.  No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[8]  Lynne Peeples,et al.  Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.

[9]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[10]  D. Lapierre,et al.  Abacavir and the potential risk of myocardial infarction , 2008, The Lancet.

[11]  O. Kirk,et al.  Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Lewis,et al.  Association of antiretroviral therapy with fibrinogen levels in HIV-infection , 2008, AIDS.

[13]  A. Phillips,et al.  Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial , 2008, Antiviral therapy.

[14]  B. Gazzard,et al.  Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis , 2008, Journal of acquired immune deficiency syndromes.

[15]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[16]  A. León,et al.  Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues. , 2007, The Journal of antimicrobial chemotherapy.

[17]  M. Egger,et al.  Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Mocroft,et al.  Chronic renal failure among HIV-1-infected patients , 2007, AIDS.

[19]  O. Kirk,et al.  Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[20]  K. Yarasheski,et al.  Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. Weber,et al.  Prevalence of risk factors for cardiovascular disease in HIV‐infected patients over time: the Swiss HIV Cohort Study , 2006, HIV medicine.

[22]  S. Shafran,et al.  The effect of low‐dose ritonavir monotherapy on fasting serum lipid concentrations , 2005, HIV medicine.

[23]  B. Gazzard,et al.  A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial , 2005, Antiviral therapy.

[24]  B. Gazzard,et al.  Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 , 2004, PLoS medicine.

[25]  P. Sax,et al.  Tolerability and Safety of HIV Protease Inhibitors in Adults , 2004, Journal of acquired immune deficiency syndromes.

[26]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[27]  J. Hulot,et al.  Renal safety of tenofovir in HIV treatment-experienced patients , 2004, AIDS.

[28]  O. Kirk,et al.  Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? , 2004, The Journal of infectious diseases.

[29]  M. Schambelan,et al.  The metabolic effects of lopinavir/ritonavir in HIV-negative men , 2004, AIDS.

[30]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[31]  Z. Fox,et al.  Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. , 2003, The Journal of infectious diseases.

[32]  O. Kirk,et al.  Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study , 2003, AIDS.

[33]  D. Podzamczer,et al.  Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load , 2003, AIDS.

[34]  S. Lange,et al.  Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.

[35]  M. Schambelan,et al.  Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection , 2000, Journal of acquired immune deficiency syndromes.

[36]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[37]  Re: "Multiple comparisons and related issues in the interpretation of epidemiologic data". , 1997, American journal of epidemiology.

[38]  A. Olshan,et al.  Multiple comparisons and related issues in the interpretation of epidemiologic data. , 1995, American journal of epidemiology.

[39]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[40]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.